homepage-top-section

The approval, which is based on results from the phase 3 BEACON CRC trial, enables to market Braftovi plus cetuximab in 27 EU member states, as well as

The regulator has provided the company with the permission to submit an investigational new drug application (IND) to use FSD-201 for the treatment of Covid-19, the disease resulted

The multi-centre, randomised, double-blind and parallel-group clinical study will evaluate the efficacy and safety of once-weekly subcutaneous injections of PB1046 in hospitalised Covid-19 patients at high risk for

The deal value of $500m will be based on the achievement of certain predetermined regulatory and commercial milestones. The transaction will provide Shionogi with global rights to Tetra’s

The IND has been submitted for a multinational phase 2b/3 study to assess re-purposed drug NP-120 (Ifenprodil) as a potential therapeutic treatment for patients with Covid-19. Ifenprodil, an

The approval enables to use of Kynmobi sublingual film for the acute and intermittent treatment of off episodes in patients with Parkinson’s disease. Kynmobi, a novel formulation of

Octagam 10% is an immune globulin intravenous (human) liquid preparation designated to treat chronic immune thrombocytopenic purpura (ITP) in adults. According to the company, the primary objective of

The approval allows Zolgensma to treat patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1or patients with

Earlier this month, the FDA has completed its review of Moderna’s investigational new drug (IND) application for mRNA-1273 to conduct Phase 2 study, which is expected to be